Enhancement of the therapeutic index: from nonmyeloablative and myeloablative toward pretargeted radioimmunotherapy for metastatic prostate cancer.

Enhancement of the therapeutic index: from nonmyeloablative and myeloablative toward pretargeted radioimmunotherapy for metastatic prostate cancer.

Item
http://www.wikidata.org/entity/Q33224551
Mucins and toll-like receptors: kith and kin in infection and cancerNanoparticles as Theranostic Vehicles in Experimental and Clinical Applications-Focus on Prostate and Breast Cancer.Imaging and drug delivery using theranostic nanoparticlesBone marrow recovery and subsequent chemotherapy following radiolabeled anti-prostate-specific membrane antigen monoclonal antibody j591 in men with metastatic castration-resistant prostate cancer.Current status of mucins in the diagnosis and therapy of cancer.90Y labeled phosphorodiamidate morpholino oligomer for pretargeting radiotherapy.Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance.The new golden era for radioimmunotherapy: not just for lymphomas anymore.General overview of radioimmunotherapy of solid tumors.The adenocarcinoma cell surface mucin receptor for alpha-fetoprotein: is the same receptor present on circulating monocytes and macrophages? A commentary.High resolution digital autoradiographic and dosimetric analysis of heterogeneous radioactivity distribution in xenografted prostate tumors.Radioimmunotherapy: a specific treatment protocol for cancer by cytotoxic radioisotopes conjugated to antibodies.
P2860

Enhancement of the therapeutic index: from nonmyeloablative and myeloablative toward pretargeted radioimmunotherapy for metastatic prostate cancer.

Item
http://www.wikidata.org/entity/Q33224551
description
2005 nî lūn-bûn
@nan
2005 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Enhancement of the therapeutic ...... or metastatic prostate cancer.
@ast
Enhancement of the therapeutic ...... or metastatic prostate cancer.
@en
type
label
Enhancement of the therapeutic ...... or metastatic prostate cancer.
@ast
Enhancement of the therapeutic ...... or metastatic prostate cancer.
@en
prefLabel
Enhancement of the therapeutic ...... or metastatic prostate cancer.
@ast
Enhancement of the therapeutic ...... or metastatic prostate cancer.
@en
P1433
P1476
P2093
P304
P31
P356
P407
P433
P478
P577
P698
P356
P1433
P1476
Enhancement of the therapeutic ...... or metastatic prostate cancer.
@en
P2093
P304
P31
P356
10.1158/1078-0432.CCR-1004-0013
P407
P433
P478
P577
P698